EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA

Davide Vito Moretti, Elizabeth Kuhn, Mark A Dubbelmann, Sietske A M Sikkes, Raphael Machado Castilhos, Silvia Chapman, Katie A Gifford, Elke Butterbrod, Rachel L Nosheny, Subjective Cognitive Decline Professional Interest Area, Alzheimer's Association ISTAART

Alzheimer's & Dementia · 2025-12 · 21 (12)

DOI: 10.1002/alz.70847 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 09.12.2025. Verfasst von Davide Vito Moretti und 9 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli Alzheimer Rehabilitation Operative Unit via Pilastroni 4, Brescia, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subjective cognitive decline (SCD)—self‐perceived cognitive worsening without objective deficits—has emerged as a clinically meaningful, potential early manifestation of Alzheimer's disease (AD). Positioned at the intersection of normal aging, neuropsychiatric symptoms, and preclinical neurodegeneration, SCD offers a unique window for early detection and intervention. However, detection heterogeneity, variable prognostic trajectories, and limited equity in assessment hinder its full clinical utility. This position paper synthesizes current evidence on SCD's diagnostic complexity, neurobiological underpinnings, and modifiable influences. We highlight the need for harmonized assessment frameworks, scalable digital tools, inclusive research, and ethically grounded biomarker disclosure practices. Importantly, we advocate for personalized, (non‐)pharmacological interventions targeting this early phase. By refining the conceptualization and operationalization of SCD, we can better identify individuals at heightened AD risk and deliver timely, equitable, and meaningful prevention strategies. SCD represents a pivotal inflection point in the dementia continuum—and a call to shift toward proactive brain health. Highlights Subjective cognitive decline (SCD) may signal early‐stage Alzheimer's despite normal test performance. Diagnostic heterogeneity limits current clinical and research utility. Biomarkers and digital tools could enhance risk stratification in SCD. Mental health and social context shape symptom reporting and outcomes. SCD offers a window for tailored (non‐drug) preventive interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansBiomarkersNeuropsychological Tests

Stichwörter der Autor:innen

Alzheimer's disease (AD)biomarkerscognitive declinediagnostic toolsmood disturbancessubjective cognitive decline (SCD)treatment strategies

Substanzen

Biomarkers

Autor:innen und Institutionen

  • IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli Alzheimer Rehabilitation Operative Unit via Pilastroni 4, Brescia, Italy.
  • German Center for Neurodegenerative Diseases (DZNE) Bonn, Bonn, Germany.
  • Department of Cognitive Disorders and Old Age Psychiatry, University Hospital Bonn, Bonn, Germany.
  • Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Clinical, Faculty of Movement and Behavioral Sciences, Neuro- and Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Zitieren

APA

Moretti, D. V., Kuhn, E., Dubbelmann, M. A., Sikkes, S. A. M., Castilhos, R. M., Chapman, S., Gifford, K. A., Butterbrod, E., Nosheny, R. L., & Subjective Cognitive Decline Professional Interest Area, Alzheimer's Association ISTAART (2025). Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA. Alzheimer's & Dementia, 21(12). https://doi.org/10.1002/alz.70847

Vancouver

Moretti DV, Kuhn E, Dubbelmann MA, Sikkes SAM, Castilhos RM, Chapman S, et al. Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA. Alzheimer's & Dementia. 2025;21(12). doi:10.1002/alz.70847

BibTeX
@article{Moretti2025,
  author = {Moretti, Davide Vito and Kuhn, Elizabeth and Dubbelmann, Mark A and Sikkes, Sietske A M and Castilhos, Raphael Machado and Chapman, Silvia and Gifford, Katie A and Butterbrod, Elke and Nosheny, Rachel L and Subjective Cognitive Decline Professional Interest Area, Alzheimer's Association ISTAART, Subjective Cognitive Decline Professional Interest Area, Alzheimer's Association ISTAART},
  title = {Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {12},
  doi = {10.1002/alz.70847}
}
Kostenlos starten →